MM-093: Completed Phase IIb enrollment

Merrimack completed enrollment of 258 patients with moderate to severe RA in a double-blind, dose-ranging, U.S. Phase IIb trial. Patients will receive methotrexate plus 1 of 3 doses of subcutaneous M...